Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) and Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.
Risk & Volatility
Aurinia Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.32, meaning that its share price is 132% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Aurinia Pharmaceuticals and Cardio Diagnostics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aurinia Pharmaceuticals | 0 | 3 | 2 | 1 | 2.67 |
| Cardio Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
Insider & Institutional Ownership
36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 9.0% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Aurinia Pharmaceuticals and Cardio Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aurinia Pharmaceuticals | 97.68% | 22.99% | 17.99% |
| Cardio Diagnostics | -40,543.75% | -89.41% | -82.81% |
Valuation and Earnings
This table compares Aurinia Pharmaceuticals and Cardio Diagnostics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aurinia Pharmaceuticals | $283.05 million | 7.52 | $287.20 million | $2.29 | 6.94 |
| Cardio Diagnostics | $10,000.00 | 592.00 | -$6.50 million | ($2.53) | -0.79 |
Aurinia Pharmaceuticals has higher revenue and earnings than Cardio Diagnostics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Aurinia Pharmaceuticals beats Cardio Diagnostics on 13 of the 15 factors compared between the two stocks.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. The Canadian company’s work has centered on therapies for conditions that can affect the kidneys and other organs. Its lead product, Lupkynis (voclosporin), is an oral medicine approved in the United States to treat adults with active lupus nephritis, a kidney complication of systemic lupus erythematosus. It is used in combination with background immunosuppressive therapy. Aurinia, formerly known as Isotechnika, developed voclosporin as a treatment for lupus nephritis.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. is a biotechnology company developing artificial intelligence-powered precision medicine products for the prevention and management of cardiovascular disease. Its approach combines genetic, epigenetic and clinical information to help identify individuals at elevated risk and support more personalized care. The company’s product portfolio includes Epi+Gen CHD, a blood-based test designed to assess an individual’s risk of developing coronary heart disease and provide information that may guide prevention strategies.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
